TNFRSF8 and lymphoma: In rituximab-resistant patients, EBV+ lymphomas have been treated with other anti-CD20 antibodies (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab) or with the CD30-directed antibody drug conjugate (ADC) brentuximab vedotin.